Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on … [Read more…]
